Particle.news

RMIT ECG Patch Enters Clinical Trial in Perth

The study will collect clinical evidence to support further development and possible regulatory clearance.

Overview

  • The prototype wireless ECG patch has begun a clinical trial this week at Midlands Medical Specialists in Perth where patients prescribed Holter monitoring will wear the device as part of the study.
  • Lubdub and RMIT say the gel-free, waterproof patch can record continuous, medical-grade heart rhythms for up to 14 days and earlier volunteer tests reported signals about 18 times cleaner than conventional Holter electrodes.
  • The trial will compare the patch’s recordings, signal quality, comfort and usability against established ECG monitors, with some participants wearing both devices for 24 to 48 hours to allow direct comparison.
  • RMIT has licensed the ECG and biomarker technology to start-up Lubdub, which raised an oversubscribed $6 million seed round in September and was named one of the Heart Foundation’s top 10 projects for 2026.
  • If validated and approved, the patch could let clinicians monitor more patients with less setup, speed diagnosis in city and remote settings, and become part of Lubdub’s planned platform that adds non-invasive biomarker tests and wearable ultrasound.